Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM2005 plus rituximab and lenalidomide in relapsed/refractory mantle cell lymphoma
CTR20262111Phase 3Active
- Sponsor
- 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.)
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HDM2005 in mantle cell lymphoma (MCL), sponsored by 杭州中美华东制药有限公司 (Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.). Started Jul 2026; status: active.
02
Drugs
HDM2005
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on CTR20262111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262111.